Exelixis to Present at the Piper Jaffray 28th Annual Healthcare Conference on November 29

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey,
Ph.D., the company’s President and Chief Executive Officer, will provide
an overview of the company at Piper Jaffray’s 28^th Annual
Healthcare Conference taking place November 29 – 30 in New York. The
Exelixis presentation is scheduled for 10:30 AM EST/7:30 AM PST on
Tuesday, November 29, 2016.

The presentation will be webcast live and may be accessed via the Event
Calendar page under Investors & Media at www.exelixis.com.
Please connect to the company’s website at least 15 minutes prior to the
presentation to ensure adequate time for any software download that may
be require to listen to the webcast. A replay will also be available at
the same location for 14 days.

About Exelixis

Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company committed
to the discovery, development and commercialization of new medicines
with the potential to improve care and outcomes for people with cancer.
Since its founding in 1994, three medicines discovered at Exelixis have
progressed through clinical development to receive regulatory approval.
Currently, Exelixis is focused on advancing cabozantinib, an inhibitor
of multiple tyrosine kinases including MET, AXL and VEGF receptors,
which has shown clinical anti-tumor activity in more than 20 forms of
cancer and is the subject of a broad clinical development program. Two
separate formulations of cabozantinib have received regulatory approval
to treat certain forms of kidney and thyroid cancer and are marketed for
those purposes as CABOMETYX™ tablets (U.S. and EU) and COMETRIQ^®
capsules (U.S. and EU), respectively. Another Exelixis-discovered
compound, COTELLIC^® (cobimetinib), a selective inhibitor of
MEK, has been approved in major territories including the United States
and European Union, and is being evaluated for further potential
indications by Roche and Genentech (a member of the Roche Group) under a
collaboration with Exelixis. For more information on Exelixis, please
visit www.exelixis.com
or follow @ExelixisInc on Twitter.

Exelixis, the Exelixis logo, COMETRIQ and COTELLIC are registered
U.S. trademarks, and CABOMETYX is a U.S. trademark.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161121006159/en/